Identification of intermediate-risk prostate cancer patients treated with radical radiotherapy suitable for neoadjuvant hormone studies

Radiotherapy and Oncology

Volumn 38, Issue 1, 1996, Pages 7-12

  Duchesne, Gillian M ^a   Bloomfield, David ^a   Wall, Patricia ^a  

^a MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Androgen deprivation; Neoadjuvant therapy; Prostate cancer; Prostate specific antigen

Indexed keywords

CYPROTERONE ACETATE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA;

EID: 0030070556     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-8140(95)01645-7     Document Type: Article

References (16)

1. Catalona, W.J. and Smith, D.S. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol. 152: 1837-1842, 1994.
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. The Lancet i: 1-15, 1992.
3. El-Galley, R.E.S., Howard, G.C.W., Hawkyard, S., Klys, H., Kerr, G.R., Duncan, W., Chisholm, G.D. and Fowler, J.W. Radical radiotherapy for localized adenocarcinoma of the prostate. A report of 191 cases. Br. J. Urol. 75: 38-43, 1995.
4. Ennis, R.D., Flynn, S.D., Fischer, D.B. and Peschel, R.E. Pre-operative serum prostate-specific antigen and Gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer: implications for the choice of primary treatment. Int. J. Radiat. Oncol. Biol. Phys. 30: 317-322, 1994.
5. Hanks, G.E., Krall, J.M., Martz, K.L., Diamond, J.J. and Kramer, S. The outcome of treatment of 313 patients with T-1 (UICC) prostate cancer treated with external beam irradiation. Int. J. Radiat. Oncol. Biol. Phys. 14: 243-248, 1988.
6. Kaplan, E.L. and Meier, P. Non-parametric estimations from incomplete observations. J. Am. Stat. Assoc. 53: 453-485, 1958.
7. Lee, R.J. and Sause, W.T. Surgically staged patients with prostatic carcinoma treated with definitive radiotherapy: fifteen-year results. Urology 43: 640-644, 1994.
8. Mameghan, H., Fisher, R., Mameghan, J. and Brook, S. Results of external beam radiotherapy in 448 patients with clinically localized adenocarcinoma of the prostate. Aust. N.Z. J. Surg. 64: 389-394, 1994.
9. Perez, C.A., Hanks, G.E., Leibel, S.A., Zietman, A.L., Fuks, Z. and Lee, W.R. Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy. Cancer 72: 3156-3173, 1993.
10. Pilepich, M.V., Bagshaw, M.A., Asbell, S.O., Hanks, G.E., Krall, J.M., Emami, B.N. and Bard, R.H. Definitive radiotherapy in resectable (Stage A2 and B) carcinoma of the prostate - results of a nationwide overview. Int. J. Radiat. Oncol. Biol. Phys. 13: 659-663, 1987.
11. Pilepich, M.V., Krall, J., Al-Sarraf, M., Roach, M., III, Doggett, R.L.S., Sause, W., Lawton, C.A., Abrams, R.A., Rotman, M., Rubin, P., Shipley, W.U., and Cox, J.D. A Phase III trial of androgen suppression before and during radiation therapy (RT) for locally advanced prostatic carcinoma: preliminary report of RTOG protocol 8610. Proc. Am. Soc. Clin. Oncol. March 12: 229, 1993.
12. Russell, K.J., Dunatov, C., Hafermann, M.D., Griffeth, J.T., Polissar, L., Pelton, J., Cole, S.B., Taylor, E.W., Wiens, L.W., Koh, W.J., Austin-Seymour, M.M., Griffin, B.R., Russell, A.M., Laramore, G.E. and Griffin, T.W. Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J. Urol. 146: 1046-1052, 1991.
13. Shearer, R.J., Davies, J.H., Gelister, J.S. and Dearnaley, D.P. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. Br. J. Urol. 69: 521-524, 1992.
14. Windsor, P.M., Baxby, K., Goodman, C. and Townell, N. Predictive value of pre-treatment PSA level on outcome following radical external beam radiotherapy for localised prostate cancer. Proceedings of the Royal College of Radiologists' (UK) Annual Scientific Meeting 1994 (abstract).
15. Zagars, G.K. The prognostic significance of a single serum prostate-specific antigen value beyond six months after radiation therapy for adenocarcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 27: 39-45, 1993.
16. Zietman, A.L., Coen, J.J., Shipley, W.U., Willett, C.G. and Efird, J.T. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J. Urol. 151: 640-645, 1994.